BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37958805)

  • 21. FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis.
    Zhang Y; Tong T
    Biochem Biophys Res Commun; 2014 Oct; 453(1):172-8. PubMed ID: 25264199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression.
    Su Y; Zhang Y; Zhao J; Zhou W; Wang W; Han B; Wang X
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3225-3243. PubMed ID: 34258652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FOXA1 in prostate cancer.
    Dong HY; Ding L; Zhou TR; Yan T; Li J; Liang C
    Asian J Androl; 2023; 25(3):287-295. PubMed ID: 36018068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype.
    Robinson JL; Hickey TE; Warren AY; Vowler SL; Carroll T; Lamb AD; Papoutsoglou N; Neal DE; Tilley WD; Carroll JS
    Oncogene; 2014 Dec; 33(50):5666-74. PubMed ID: 24292680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOXA1 regulates alternative splicing in prostate cancer.
    Del Giudice M; Foster JG; Peirone S; Rissone A; Caizzi L; Gaudino F; Parlato C; Anselmi F; Arkell R; Guarrera S; Oliviero S; Basso G; Rajan P; Cereda M
    Cell Rep; 2022 Sep; 40(13):111404. PubMed ID: 36170835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.
    Gerhardt J; Montani M; Wild P; Beer M; Huber F; Hermanns T; Müntener M; Kristiansen G
    Am J Pathol; 2012 Feb; 180(2):848-61. PubMed ID: 22138582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1.
    Wang L; Xu M; Kao CY; Tsai SY; Tsai MJ
    J Clin Invest; 2020 Apr; 130(4):1782-1792. PubMed ID: 31874106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Label-free quantitative proteomic analysis identifies the oncogenic role of FOXA1 in BaP-transformed 16HBE cells.
    Wang Y; Li L; Hao M; Fu D; Chen J; Zhou C; Fu J; Yao B; Chang B; Zhao P
    Toxicol Appl Pharmacol; 2020 Sep; 403():115160. PubMed ID: 32717239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-Wide Analysis of the FOXA1 Transcriptional Network Identifies Novel Protein-Coding and Long Noncoding RNA Targets in Colorectal Cancer Cells.
    Lazar SB; Pongor L; Li XL; Grammatikakis I; Muys BR; Dangelmaier EA; Redon CE; Jang SM; Walker RL; Tang W; Ambs S; Harris CC; Meltzer PS; Aladjem MI; Lal A
    Mol Cell Biol; 2020 Oct; 40(21):. PubMed ID: 32839292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.
    Hu DG; Gardner-Stephen D; Severi G; Gregory PA; Treloar J; Giles GG; English DR; Hopper JL; Tilley WD; Mackenzie PI
    Mol Pharmacol; 2010 Oct; 78(4):714-22. PubMed ID: 20628005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.
    Sunkel B; Wu D; Chen Z; Wang CM; Liu X; Ye Z; Horning AM; Liu J; Mahalingam D; Lopez-Nicora H; Lin CL; Goodfellow PJ; Clinton SK; Jin VX; Chen CL; Huang TH; Wang Q
    Nucleic Acids Res; 2016 May; 44(9):4105-22. PubMed ID: 26743006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Forkhead‑box A1 regulates tumor cell growth and predicts prognosis in colorectal cancer.
    Park YL; Kim SH; Park SY; Jung MW; Ha SY; Choi JH; Myung DS; Cho SB; Lee WS; Kim HS; Joo YE
    Int J Oncol; 2019 Jun; 54(6):2169-2178. PubMed ID: 31081047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6.
    Yamaguchi N; Nakayama Y; Yamaguchi N
    J Biol Chem; 2017 May; 292(20):8136-8148. PubMed ID: 28270510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer.
    Sahu B; Laakso M; Ovaska K; Mirtti T; Lundin J; Rannikko A; Sankila A; Turunen JP; Lundin M; Konsti J; Vesterinen T; Nordling S; Kallioniemi O; Hautaniemi S; Jänne OA
    EMBO J; 2011 Sep; 30(19):3962-76. PubMed ID: 21915096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Kim J; Jin H; Zhao JC; Yang YA; Li Y; Yang X; Dong X; Yu J
    Oncogene; 2017 Jul; 36(28):4072-4080. PubMed ID: 28319070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer.
    Fu X; Jeselsohn R; Pereira R; Hollingsworth EF; Creighton CJ; Li F; Shea M; Nardone A; De Angelis C; Heiser LM; Anur P; Wang N; Grasso CS; Spellman PT; Griffith OL; Tsimelzon A; Gutierrez C; Huang S; Edwards DP; Trivedi MV; Rimawi MF; Lopez-Terrada D; Hilsenbeck SG; Gray JW; Brown M; Osborne CK; Schiff R
    Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6600-E6609. PubMed ID: 27791031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lysosome-dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer.
    Celada SI; Li G; Celada LJ; Lu W; Kanagasabai T; Feng W; Cao Z; Salsabeel N; Mao N; Brown LK; Mark ZA; Izban MG; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Wang X; Chen Z
    Mol Oncol; 2023 Oct; 17(10):2126-2146. PubMed ID: 37491794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
    Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
    Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical significance of forkhead box protein A1 and its role in colorectal cancer.
    Ma W; Jiang J; Li M; Wang H; Zhang H; He X; Huang L; Zhou Q
    Mol Med Rep; 2016 Sep; 14(3):2625-31. PubMed ID: 27484093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mutational landscape of lethal castration-resistant prostate cancer.
    Grasso CS; Wu YM; Robinson DR; Cao X; Dhanasekaran SM; Khan AP; Quist MJ; Jing X; Lonigro RJ; Brenner JC; Asangani IA; Ateeq B; Chun SY; Siddiqui J; Sam L; Anstett M; Mehra R; Prensner JR; Palanisamy N; Ryslik GA; Vandin F; Raphael BJ; Kunju LP; Rhodes DR; Pienta KJ; Chinnaiyan AM; Tomlins SA
    Nature; 2012 Jul; 487(7406):239-43. PubMed ID: 22722839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.